Immunotherapy is transforming how certain cancers are treated, but the path to getting it paid for in the UK is anything but simple. For a patient with advanced non-small cell lung cancer, the time between a drug being proven effective and the NHS agreeing to fund it can stretch for months or even years, depending on how NICE assesses the cost per quality-adjusted life year (QALY). That gap between clinical evidence and reimbursement is where the real financial and medical stakes sit.
Disclosure: Some links on this page are affiliate links. If you make a purchase through them, Britwealth may earn a commission at no extra cost to you. We only include products and services that are relevant to the topic.
This article is general information only and does not constitute professional advice. For your specific situation, consult a qualified professional.
If you’re navigating outpatient immunotherapy in the UK — whether through the NHS or privately — the reimbursement landscape is shaped by a handful of fixed rules and a lot of moving parts. NICE sets the bar, but how that bar applies to your specific treatment, your hospital trust, and your funding route can vary. Here’s what you actually need to know.
What the research reveals about immunotherapy reimbursement in the UK
The central concept here is the quality-adjusted life year, or QALY. It’s the metric NICE uses to decide whether a drug is worth the money.
What I tend to notice is that most people focus on whether a drug works, not on whether it meets the cost-effectiveness bar. But in the UK system, that second question often determines whether you actually get it.
NICE thresholds, patient access schemes, and what they mean for your wallet
The £20,000–£30,000 per QALY threshold isn’t a hard cap — NICE can approve drugs above it, especially for end-of-life treatments or rare diseases. But crossing that line usually triggers extra conditions. That’s where Patient Access Schemes (PAS) come in.
There are two main types of PAS. A simple discount scheme means the manufacturer sells the drug to the NHS at a reduced price. An outcome-based scheme ties payment to how well the drug actually performs in patients — if it doesn’t work as expected, the NHS pays less. These schemes are confidential, so you won’t see the exact discount, but they’re the reason many expensive immunotherapies get approved at all.
→ Scroll right to see all columns
| Reimbursement Route | How It Works | Who It Affects |
|---|---|---|
| NHS routine commissioning | NICE approves; NHS England funds via local trusts | Patients treated within NHS hospitals |
| Cancer Drugs Fund (CDF) | Conditional approval while more data is collected | Patients whose drugs need further evidence |
| Patient Access Scheme (discount) | Manufacturer offers lower price to NHS | All NHS patients for that drug |
| Private outpatient care | Patient or insurer pays full cost | Those with private health insurance or self-funding |
For a patient on a typical NHS pathway, the difference between a drug being in the Cancer Drugs Fund versus fully commissioned can mean months of uncertainty. The CDF allows access while NICE gathers real-world evidence, but it’s not permanent approval. If the data doesn’t hold up, the drug can be withdrawn.
Where the system catches people out
Assuming NICE approval means immediate access
Even after NICE says yes, local NHS trusts can take months to implement the decision. A study comparing pembrolizumab reimbursement across countries found that NICE and Israel approved one condition at the same time, but Israel approved two conditions earlier than the UK. The gap isn’t just about the national decision — it’s about local rollout. If your trust hasn’t updated its formulary, you may face delays even with a positive NICE recommendation.
Overlooking the Cancer Drugs Fund time limit
Drugs in the CDF have a fixed window — usually two years — to generate enough evidence for full approval. If the real-world data doesn’t meet expectations, the drug can be removed. That means a patient who starts treatment under the CDF could find their drug delisted mid-course. The fix is to ask your oncologist whether the drug has full commissioning or CDF status before starting, and what the contingency plan is if it’s withdrawn.
Mistaking private insurance coverage for full reimbursement
Private health insurance in the UK often covers outpatient immunotherapy, but policies vary widely. Some exclude experimental treatments, others cap the total payout per year. If your policy has a £50,000 annual limit and a full course of immunotherapy runs toward £45,000, you could exhaust your cover on one treatment. Always check the policy exclusions and annual limits before assuming you’re covered.
Ignoring the biosimilar timeline
Biosimilars — cheaper versions of biologic drugs — are expected around 2028. That’s still years away, but it matters for planning. If you’re considering a private treatment now, check whether a biosimilar is in development for that drug. If one is, the price may drop significantly within a few years, which could affect whether your insurer or the NHS is willing to fund the current version.
How to navigate outpatient immunotherapy reimbursement in practice
Start with the NICE appraisal
Every immunotherapy drug goes through a NICE Single Technology Appraisal (STA) or Multiple Technology Appraisal (MTA). The appraisal reviews clinical trial data, compares the drug to existing treatments, and calculates the cost per QALY. You can find the current status of any drug on the NICE website. If the drug hasn’t been appraised yet, or if the appraisal is ongoing, there’s no guaranteed NHS funding route. Your oncologist can tell you whether the drug is in the pipeline.
Check the Cancer Drugs Fund list
If the drug isn’t fully approved, it may be in the CDF. The CDF list is updated regularly. Drugs in the fund are available on the NHS while further evidence is collected. The key question to ask: is the drug in the CDF with a managed entry agreement, or is it still awaiting appraisal? The answer determines whether you can start treatment now or need to wait.
Understand the Patient Access Scheme
If the drug is approved but expensive, there’s likely a PAS in place. These schemes are confidential, but your hospital’s pharmacy team will know the details. The practical effect is that the NHS pays less than the list price, which makes the drug viable. You don’t need to do anything — the discount is applied automatically — but it’s worth knowing that the price you see quoted online isn’t what the NHS actually pays.
Consider private options with clear cost limits
If the NHS route is blocked — either because the drug isn’t approved or because local implementation is delayed — private outpatient care is an option. But the costs vary enormously. In the UK, private immunotherapy can exceed US prices, which can approach $45,000 per course. Abroad, costs can be up to 85% lower. Turkey offers treatment from $2,200–$5,400; Israel from $2,400–$4,900; Germany from $3,500. If you’re considering treatment abroad, factor in travel, accommodation, and follow-up care. A travel health insurance policy that covers medical treatment abroad is essential.
Watch for the biosimilar shift
The first biosimilar immunotherapies are expected around 2028. When they arrive, the cost of treatment could drop significantly, which may push NICE to approve drugs that are currently above threshold. If you’re on a long-term treatment plan, ask your oncologist whether a biosimilar version of your drug is in development. If it is, the reimbursement landscape could change within your treatment window.
Frequently asked questions
Can I get immunotherapy on the NHS if NICE hasn’t approved it yet? ▾
What happens if my drug is removed from the Cancer Drugs Fund mid-treatment? ▾
Does private health insurance in the UK cover outpatient immunotherapy? ▾
How long does NICE take to approve a new immunotherapy drug? ▾
Are biosimilars the same as the original immunotherapy? ▾
Can I get immunotherapy abroad and then continue on the NHS? ▾
The real cost of waiting for reimbursement
The gap between a drug being proven effective and the NHS funding it isn’t just a bureaucratic delay — it’s a period where patients either pay privately, travel abroad, or go without. The MANIFEST programme, a £21.9m UK-wide research project, is recruiting 3,000 patients starting immunotherapy to study biomarkers and side effects. That kind of real-world data could speed up future appraisals, but it won’t help someone waiting for a decision today. If you’re in that position, the most practical step is to know exactly where your drug stands in the NICE pipeline, what your insurance covers, and what the private alternatives cost — before you need them.
Remember: this article is general information only. For advice on your specific situation, speak to a qualified professional.
If this was useful, you might also want to read The Hidden Costs of Not Having Private Health Insurance in the UK: A Reality Check.
Sources and Further Reading
The future of healthcare: personalised cover with private insurance — Explores how private insurance can fill gaps in NHS coverage, including for high-cost treatments.
Pharma Guidelines (2024). Ensuring Equitable Access: An Overview of the NHS Drug Reimbursement Policy in the UK. 🔗
Bookimed (2024). The Cost of Immunotherapy for Cancer: A Global Comparison and Affordable Options. 🔗
Action Kidney Cancer (2024). Multi-Million Pound UK-Wide Research into Cancer Immunotherapy. 🔗
Taylor & Francis Online (2023). The Reimbursement Process in Three National Healthcare Systems. 🔗
